Genscript ProBio licences STR technology from mAbsolve
Genscript ProBio have licenced mAbsolves first in class solution for abolising antibody effector function to enable their worldwide ...
Read More Geoff Hale to present at Promega Biologics Symposium
On Thursday 22nd September, our CEO, Geoff Hale, will be presenting some of our recent work on the ...
Read More mAbsolve publish paper in mAbs
Today our CEO and CSO, Geoff Hale and Ian Wilkinson, have had a new article published in mAbs. ...
Read More Ian Wilkinson to give webinar to Chinese Antibody Society
On Saturday 10th September our CSO, Ian Wilkinson, will be giving a webinar to the Chinese Antibody Society ...
Read More Patent granted for mAbsolve’s Fc silencing technology
On 5 Jul 2022 the UK Intellectual Property Office granted Patent number GB2595299 to mAbsolve. Publication of the ...
Read More Scancell license STR technology
Scancell, a UK based company developing anti-glycan antibodies, have today announced an agreement with mAbsolve to license our ...
Read More Antibody Analytics Licenses Novel Fc Silencing Technology from mAbsolve
Fully silent antibodies as true negative controls for in vitro and cell-based effector function assays Antibody Analytics Ltd., ...
Read More mAbsolve to present STR technology at PEGS Boston 2022
Our CSO, Ian Wilkinson, will be attending PEGS Boston in the week of 2-6th May. Our antibody silencing ...
Read More mAbsolve to present webinar hosted by The Antibody Society
Our CSO, Ian Wilkinson, will be presenting on the importance of attenuating effector functions in therapeutics antibodies as ...
Read More